AstraZeneca PLC - Form 6-K Filing Summary

This report details the positive high-level results from the DeLLphi-305 Phase III trial for AstraZeneca's Imfinzi (durvalumab) in combination with Amgen's Imdelltra® (tarlatamab). The combination demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) when used as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) patients who had not progressed after standard induction chemotherapy. This combination is the first immunotherapy with a bispecific T-cell engager to show a survival benefit in this setting, reinforcing Imfinzi's role as a backbone immunotherapy for SCLC. The safety and tolerability profile was consistent with known individual treatment profiles, with no new safety signals identified. These results are expected to be presented at an upcoming medical meeting and submitted to regulatory authorities. The trial involved 563 patients and met its primary endpoint of improved OS.